实用医学杂志 ›› 2023, Vol. 39 ›› Issue (5): 538-543.doi: 10.3969/j.issn.1006⁃5725.2023.05.003

• 专题报道 • 上一篇    下一篇

嵌合抗原受体基因修饰T细胞免疫疗法在肺癌治疗中的研究进展

陈富坤 吕娟 邓智勇   

  1. 云南省肿瘤医院、昆明医科大学第三附属医院核医学科(昆明650118)
  • 出版日期:2023-03-10 发布日期:2023-03-10
  • 通讯作者: 邓智勇 E⁃mail:13888158986@163.com
  • 基金资助:
    国家自然科学地区科学基金项目(编号:82160343)

Effect of chimeric antigen receptor gene⁃modified T⁃cell immunotherapy for lung cancer:A systematic review

CHEN Fukun,LV Juan,DENG Zhiyong   

  1. Department of Nuclear Medicine,Yunnan Cancer Hospital,the Third Affiliated Hospital of Kunming Medical University,Kunming 650118,China
  • Online:2023-03-10 Published:2023-03-10
  • Contact: DENG Zhiyong E⁃mail:13888158986@163.com

摘要:

肺癌是全世界所有癌症中发病率和病死率最高的恶性肿瘤之一,目前仍缺乏较好的治疗手 段。嵌合抗原受体基因修饰 T(CAR⁃T)细胞免疫疗法作为一种新的治疗方法在血液系统恶性肿瘤中疗效 显著,也为肺癌等实体肿瘤的免疫治疗开辟了新途径。然而,由于实体瘤的异质性、肿瘤微环境免疫抑制、 肿瘤靶抗原逃逸及脱靶毒性等问题,造成 CAR⁃T 细胞免疫疗法在肺癌治疗中的应用存在挑战和障碍。本 文总结了 CAR⁃T 细胞免疫疗在肺癌治疗中的最新研究进展,包括 CAR⁃T 细胞生物学特征、靶点选择、早期 临床研究和治疗不良反应,并提出肺癌CAR⁃T细胞免疫疗法的优化策略,旨在为肺癌的临床免疫治疗提供 新思路。

关键词:

Abstract:

Lung cancer is one of the malignancies with the highest incidence and mortality among all cancers worldwide,but still no effective treatment is available. Chimeric antigen receptor gene modified⁃T(CAR⁃T cells,a novel adoptive immunotherapy strategy,not only have been used successfully against hematological tumors but also have opened up new approach for immunotherapy of solid tumors,including lung cancer. However,CAR⁃ T cell immunotherapy still has challenges and obstacles in the treatment of lung cancer due to the heterogeneity of solid tumors,tumor microenvironment immunosuppression,tumor target antigen escape,and off ⁃target toxicity etc. In this review,we summarized the latest research progress on CAR⁃T cell immunotherapy for lung cancer including CAR ⁃T cell biological characteristics,targets selection,early clinical research,therapeutic adverse effects,and proposed optimization strategies for CAR⁃T cell immunotherapy in lung cancer,aiming to provide new ideas for clinical immunotherapy for lung cancer.

Key words: lung cancer, chimeric antigen receptor gene modified?T cells, immunotherapy, tumor antigen